Policy | April 01, 2024
Venus Remedies receives Rs. 2.50 crore under PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Establishment of 220 smart classrooms across Uttar Pradesh, Uttarakhand, and Himachal Pradesh
Executes the first project for developing and manufacturing a novel anticancer mAb
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Subscribe To Our Newsletter & Stay Updated
